Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Effects of Sufentanil on proliferation, migration and epithelial-mesenchymal transition of endometrial cancer
1Department of Pharmacy, The 2nd Affiliated Hospital of Wenzhou Medical University, 325000 Wenzhou, Zhejiang, China
2Department of Obstetrics and Gynecology, The 2nd Affiliated Hospital of Wenzhou Medical University, 325000 Wenzhou, Zhejiang, China
3Department of Anesthesiology, The 2nd Affiliated Hospital of Wenzhou Medical University, 325000 Wenzhou, Zhejiang, China
DOI: 10.22514/ejgo.2023.106 Vol.44,Issue 6,December 2023 pp.122-127
Submitted: 21 July 2023 Accepted: 25 August 2023
Published: 15 December 2023
*Corresponding Author(s): Mimi Dai E-mail: Daimimi_666@163.com
To investigate the impact of Sufentanil on the progression of endometrial cancer (EC), including its proliferation, migration, epithelial-mesenchymal transition and underlying mechanism. The effects of Sufentanil on EC cell growth were evaluated using Cell counting kit-8 (CCK-8) and colony formation assays, while wound healing and transwell assays were performed to assess the influence on motility. In addition, immunoblot assays were performed to determine its role in EC cell epithelial-mesenchymal transition (EMT) and the associated underlying mechanism. Sufentanil demonstrated the ability to inhibit EC cell growth, migration, invasion and EMT process through the inhibition of the Protein Kinase B (AKT)/nuclear factor kappa-B (NF-κB) axis, thereby contributing to the repression of EC progression. Sufentanil effectively inhibited the proliferation, migration and EMT of endometrial cancer, demonstrating a potentially effective approach against EC.
Endometrial cancer (EC); Sufentanil; Migration; EMT; AKT/NF-κB pathway
Chen Cheng,Mimi Dai,Shishi Zheng,Yujie Wu,Li Shu,Huimin Wu. Effects of Sufentanil on proliferation, migration and epithelial-mesenchymal transition of endometrial cancer. European Journal of Gynaecological Oncology. 2023. 44(6);122-127.
[1] Zhai L, Yang X, Cheng Y, Wang J. Glutamine and amino acid metabolism as a prognostic signature and therapeutic target in endometrial cancer. Cancer Medicine. 2023; 12: 16337–16358.
[2] Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. 2023; 19: 1709–1714.
[3] Li Q, Wang T, Bin Y, Zhao L. Positive rate of malignant cells in endometrial cytology samples of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer patients: a systematic review and meta-analysis. Journal of Cytology. 2023; 40: 51–57.
[4] Huang P, Qian Y, Xia Y, Wang S, Xu C, Zhu X, et al. Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer. Journal of Cellular and Molecular Medicine. 2023; 27: 2385–2397.
[5] Chang CS, Lai YL, Choi CH, Kim TJ, Lee JW, Kim BG, et al. Comparison of minimally invasive and open surgery for the treatment of endometrial cancer with a high risk of recurrence: a propensity score matching study in Korea and Taiwan. Annals of Surgical Oncology. 2023; 30: 6855–6864.
[6] Brus L, Grimm-Glang D, Krawczyk N, Fehm T, Rody A, Paluchowski P, et al. Circulating tumor cells in metastatic breast cancer: ready for clinical practice? European Journal of Gynaecological Oncology. 2022; 43: 4–8.
[7] Liu L, Huan L, Zhang Y, Wei W, Chen Z, Xu D, et al. Ubiquitin-specific protease 8 inhibits lipopolysaccharide-triggered pyroptosis of human bronchial epithelial cells by regulating PI3K/AKT and NF-κB pathways. Allergologia et Immunopathologia. 2022; 50: 96–103.
[8] Liu C, Wang Q, Niu L. Sufentanil inhibits Pin1 to attenuate renal tubular epithelial cell ischemia-reperfusion injury by activating the PI3K/AKT/FOXO1 pathway. International Urology and Nephrology. 2023; 55: 1903–1916.
[9] Tan H, Wang C, Jiang Y, Shi Q, Liang W, Li D. Postoperative effect of Sufentanil preemptive analgesia combined with psychological intervention on breast cancer patients. BMC Anesthesiology. 2023; 23: 170.
[10] Tire Y, Sarkilar G, Esen H, Onoglu R, Uzun ST. The effect of intrathecal Sufentanil preconditioning against myocardial ischemia-reperfusion injury. Bratislava Medical Journal. 2018; 119: 240–244.
[11] Xu S, Li X, Li W, Ma N, Ma H, Cui J, et al. Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition. Clinical & Experimental Metastasis. 2023; 40: 149–160.
[12] Li J, Li S, Yu L, Wei J, Li S, Tan H. The effects of Resistin gene polymorphism on pain thresholds and postoperative Sufentanil consumption in gastric cancer patients. Journal of Pain Research. 2022; 15: 1995–2004.
[13] Lin Y, Miao Z, Wu Y, Ge F, Wen Q. Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with Sufentanil controlled analgesia—a randomized controlled trial. BMC Anesthesiology. 2019; 19: 236.
[14] Tang H, Li C, Wang Y, Deng L. Sufentanil inhibits the proliferation and metastasis of esophageal cancer by inhibiting the NF-κB and snail signaling pathways. Journal of Oncology. 2021; 2021: 7586100.
[15] Dias S, Trovisco S, Neves I, Miranda L, Valente R. Efficacy and safety of Sufentanil infusion for postoperative analgesia in cancer surgery: a retrospective cohort study. Cureus. 2023; 15: e38993.
[16] Mutch DG. Targeted therapy in endometrial cancer: making progress. Cancer. 2016; 122: 3428–3429.
[17] Eritja N, Chen B, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017; 13: 608–624.
[18] Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos M, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstetrics and Gynecology International. 2010; 2010: 1–11.
[19] Wu W, Wei N, Jiang CN, Cui S, Yuan J. Effects of Sufentanil on human gastric cancer cell line SGC-7901 in vitro. Central-European Journal of Immunology. 2014; 39: 299–305.
[20] Li M, Gu K, Kong Q, Wang G, Gu J. Sufentanil inhibits the metastasis and immune response via mediating the NF-κB pathway. To be published in Immunopharmacology and Immunotoxicology. 2023. [Preprint].
[21] Li H, Chen M, Yang Z, Xu C, Yu Q, Song J, et al. Amorphophalli Rhizoma inhibits breast cancer growth, proliferation, migration, and invasion via the PI3K/AKT pathway. Journal of Ethnopharmacology. 2022; 286: 114926.
[22] Xu Y, Fang R, Shao J, Cai Z. Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway. Bioscience Reports. 2021; 41: BSR20210093.
[23] Feng Q, Yang Y, Qiao Y, Zheng Y, Yu X, Liu F, et al. Quercetin ameliorates diabetic kidney injury by inhibiting ferroptosis via activating Nrf2/HO-1 signaling pathway. The American Journal of Chinese Medicine. 2023; 51: 997–1018.
[24] Lin L, Gao Y, Hu X, Ouyang J, Liu C. Pentamidine inhibits proliferation, migration and invasion in endometrial cancer via the PI3K/AKT signaling pathway. BMC Women’s Health. 2022; 22: 470.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top